Asia Pacific perspectives on the second year of the COVID-19 pandemic: A follow-up survey.
anaphylaxis
endemic diseases
prophylaxis
therapeutics
vaccination
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
08
06
2022
received:
22
04
2022
accepted:
20
06
2022
entrez:
30
7
2022
pubmed:
31
7
2022
medline:
3
8
2022
Statut:
ppublish
Résumé
The Coronavirus disease 2019 (COVID-19) pandemic is currently in its third year. This follow-up survey was commissioned by the Asia Pacific Association of Allergy Asthma and Clinical Immunology (APAAACI) Task Force on COVID-19 to compare and contrast changes in the epidemiology, clinical profile, therapeutics and public health measures of the pandemic in the Asia Pacific region. A questionnaire-based survey comprising 32 questions was electronically sent out to all 15 member countries of APAAACI using Survey Monkey® from 1 December 2021 to 28 February 2022. Seventeen responses were received from 14/15 (93.4%) member countries and 3 individual members. Mild-to-moderate COVID-19 predominated over severe infection, largely contributed by COVID-19 vaccination programmes in the region. The incidence of vaccine adverse reactions in particular anaphylaxis from messenger ribonucleic acid (mRNA) vaccines was no longer as high as initially anticipated, although perimyocarditis remains a concern in younger males. Novel therapeutics for mild-to-moderate disease including neutralizing antibodies casirivimab/imdevimab (REGEN-COV®) and sotrovimab (Xevudy®), anti-virals Paxlovid® (nirmatrelvir and ritonavir) and Molnupiravir pre-exposure prophylaxis for high-risk persons with Tixagevimab and Cilgavimab (Evusheld) are now also available to complement established therapeutics (e.g., remdesivir, dexamethasone and baricitinib) for severe disease. In the transition to endemicity, public health measures are also evolving away from containment/elimination strategies. With access to internationally recommended standards of care including public health preventive measures, therapeutics and vaccines among most APAAACI member countries, much progress has been made over the 2-year period in minimizing the morbidity and mortality from COVID-19 disease.
Sections du résumé
BACKGROUND
The Coronavirus disease 2019 (COVID-19) pandemic is currently in its third year. This follow-up survey was commissioned by the Asia Pacific Association of Allergy Asthma and Clinical Immunology (APAAACI) Task Force on COVID-19 to compare and contrast changes in the epidemiology, clinical profile, therapeutics and public health measures of the pandemic in the Asia Pacific region.
METHODS
A questionnaire-based survey comprising 32 questions was electronically sent out to all 15 member countries of APAAACI using Survey Monkey® from 1 December 2021 to 28 February 2022.
RESULTS
Seventeen responses were received from 14/15 (93.4%) member countries and 3 individual members. Mild-to-moderate COVID-19 predominated over severe infection, largely contributed by COVID-19 vaccination programmes in the region. The incidence of vaccine adverse reactions in particular anaphylaxis from messenger ribonucleic acid (mRNA) vaccines was no longer as high as initially anticipated, although perimyocarditis remains a concern in younger males. Novel therapeutics for mild-to-moderate disease including neutralizing antibodies casirivimab/imdevimab (REGEN-COV®) and sotrovimab (Xevudy®), anti-virals Paxlovid® (nirmatrelvir and ritonavir) and Molnupiravir pre-exposure prophylaxis for high-risk persons with Tixagevimab and Cilgavimab (Evusheld) are now also available to complement established therapeutics (e.g., remdesivir, dexamethasone and baricitinib) for severe disease. In the transition to endemicity, public health measures are also evolving away from containment/elimination strategies.
CONCLUSIONS
With access to internationally recommended standards of care including public health preventive measures, therapeutics and vaccines among most APAAACI member countries, much progress has been made over the 2-year period in minimizing the morbidity and mortality from COVID-19 disease.
Identifiants
pubmed: 35906963
doi: 10.1111/cea.14191
pmc: PMC9353384
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Antibodies, Neutralizing
0
COVID-19 Vaccines
0
Drug Combinations
0
casirivimab and imdevimab drug combination
0
tixagevimab
0
cilgavimab
1KUR4BN70F
sotrovimab
1MTK0BPN8V
imdevimab
2Z3DQD2JHM
casirivimab
J0FI6WE1QN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
965-973Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Autoimmun Rev. 2022 Jan;21(1):102927
pubmed: 34474172
Eur J Med Res. 2022 Feb 12;27(1):23
pubmed: 35151362
BMJ Glob Health. 2022 Feb;7(2):
pubmed: 35228258
JAMA. 2022 Jan 25;327(4):384-385
pubmed: 35076671
Lancet. 2022 Jan 1;399(10319):2-3
pubmed: 34942104
Clin Infect Dis. 2022 Feb 03;:
pubmed: 35134143
Clin Exp Allergy. 2022 Aug;52(8):965-973
pubmed: 35906963
N Engl J Med. 2021 Dec 2;385(23):2189-2190
pubmed: 34874636
Clin Exp Allergy. 2022 Mar;52(3):465-469
pubmed: 34854156
Allergy. 2021 Sep;76(9):2998-2901
pubmed: 33948966
Neurology. 2021 Nov 23;97(21):e2136-e2147
pubmed: 34610990
J Allergy Clin Immunol. 2021 Jun;147(6):2075-2082.e2
pubmed: 33857566
Vaccine. 2022 Mar 15;40(12):1768-1774
pubmed: 35153093
Lancet. 2022 Feb 19;399(10326):757-768
pubmed: 34942102
Diagnostics (Basel). 2022 Feb 02;12(2):
pubmed: 35204473
Clin Exp Allergy. 2021 Sep;51(9):1107-1120
pubmed: 34351016
Nat Med. 2022 Jan;28(1):39-50
pubmed: 35064248
Hum Vaccin Immunother. 2022 Nov 30;18(5):2045857
pubmed: 35240940
Front Microbiol. 2021 Jun 23;12:698169
pubmed: 34248921
J Med Virol. 2022 May;94(5):1821-1824
pubmed: 34936120
N Engl J Med. 2022 Jan 6;386(1):95
pubmed: 34936738
Int J Mol Sci. 2022 Feb 11;23(4):
pubmed: 35216104
N Engl J Med. 2022 Jan 20;386(3):264-272
pubmed: 34995029
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1344-1348
pubmed: 34555007
Clin Med (Lond). 2022 Jan;22(1):63-70
pubmed: 35078796
World Allergy Organ J. 2021 Feb;14(2):100517
pubmed: 33558825
Nat Rev Immunol. 2020 Oct;20(10):587-588
pubmed: 32778829
Lancet. 2021 Oct 30;398(10311):1547-1551
pubmed: 34619099
Ann Allergy Asthma Immunol. 2022 Feb;128(2):153-160
pubmed: 34798275
JAMA Intern Med. 2022 Apr 01;182(4):376-385
pubmed: 35188528
Ann Med. 2022 Dec;54(1):516-523
pubmed: 35118917
MMWR Morb Mortal Wkly Rep. 2021 Nov 05;70(44):1545-1552
pubmed: 34735422
Lancet. 2021 Dec 18;398(10318):2209-2211
pubmed: 34922657
APMIS. 2022 Feb;130(2):101-110
pubmed: 34894016
Vaccine. 2022 Jan 21;40(2):183-186
pubmed: 34863620
Ann Intern Med. 2022 May;175(5):701-709
pubmed: 35226522
MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):749-752
pubmed: 34014913
Vaccines (Basel). 2022 Feb 17;10(2):
pubmed: 35214779
MMWR Morb Mortal Wkly Rep. 2021 Nov 12;70(45):1579-1583
pubmed: 34758012
J Allergy Clin Immunol Pract. 2021 Oct;9(10):3546-3567
pubmed: 34153517
Expert Opin Investig Drugs. 2022 Jan;31(1):41-58
pubmed: 35164631